Clinical Trials Using Trametinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trametinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-30 of 30

  • Dabrafenib Mesylate, Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Patients with Stage IIIB-IV Melanoma

    This phase I / II trial studies the side effects and how well dabrafenib mesylate, trametinib, and 6 melanoma helper peptide vaccine work in treating patients with stage IIIB-IV melanoma. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines, such as 6 melanoma helper peptide vaccine, made from peptides derived from melanoma proteins, may help the body build an effective immune response to kill tumor cells that express melanoma-specific antigens. Giving dabrafenib, trametinib, and 6 melanoma helper peptide vaccine may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Dabrafenib and Trametinib before and after Surgery in Treating Patients with Stage IIIB-C Melanoma with BRAF V600 Mutation

    This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving dabrafenib and trametinib after surgery may kill any remaining tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Trametinib in Treating Patients with Advanced Cancer with or without Hepatic Dysfunction

    This phase I trial studies the side effects and best dose of trametinib in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib may stop the growth of tumor cells by blocking proteins needed for cell growth. When these proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will then die. Hepatic dysfunction is frequently found in patients with advanced cancer and usually prevents patients from receiving standard treatments or from participating in clinical trials. Patients may also need dose adjustments or absorb drugs differently. Trametinib may be a better treatment for patients with advanced cancers and hepatic dysfunction.
    Location: 5 locations

  • Dabrafenib and / or Trametinib Rollover Study

    This study is to provide access for patients who are receiving treatment with dabrafenib and / or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
    Location: See Clinical Trials.gov

  • Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

    Background: Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene. Researchers think a mix of drugs can slow the progression of gene-mutated cancers of the biliary tract. Objective: To see if using a combination of trametinib and hydroxychloroquine (HCQ) increases the period of time it takes for a person s bile tract carcinoma (BTC) to get worse. Eligibility: Adults age 18 and older with BTC. Design: Participants will be screened with a physical exam, medical history, and cancer history. Their ability to do their normal activities will be assessed. They will have blood and urine tests. They will give a tumor sample. They will have heart tests. They may talk with a heart doctor. They may have an eye exam. They may have a tuberculosis test. They will have computer tomography (CT) scans of the chest, abdomen, and pelvis. They may have magnetic resonance imaging (MRI) scans of the chest, abdomen, pelvis. Participants will repeat some screening tests throughout the study. Participants will take HCQ and trametinib tablets by mouth daily in 28-day cycles. They will have study visits once a month. They will take the drugs until they have bad side effects or the drugs stop working. Participants will have one more tumor biopsies during the treatment. They will have blood taken often. One month after treatment ends, participants will have a safety follow-up visit. Then they will be called or emailed every 6 months for the rest of their life....
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland